Myqorzo-Aficamten
Myqorzo (aficamten) is a prescription oral therapy indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults to improve functional capacity and reduce symptoms. It is a cardiac myosin inhibitor that binds to the motor protein myosin in the heart muscle, reducing excessive contractile force and decreasing left ventricular outflow tract obstruction that […]
Lerochol-Lerodalcibep-Liga
Lerochol is a novel cholesterol-lowering biologic developed to address unmet needs in the management of hypercholesterolemia. It is indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) levels in adults, including those with heterozygous familial hypercholesterolemia (HeFH). It is designed to target PCSK9-mediated pathways, thereby enhancing LDL receptor recycling and […]
Exdensur-Depemokimab-Ulaa
Exdensur (depemokimab-ulaa) is an ultra-long-acting biologic therapy indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older. It is administered as a subcutaneous injection every six months in addition to standard asthma medications to help reduce the frequency of asthma exacerbations. It is […]
Voyxact Sibeprenlimab-Szsi
Voyxact® (sibeprenlimab-szsi) is an FDA-approved prescription medicine used to reduce proteinuria (protein in the urine) in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. This approval is under the FDA’s accelerated approval pathway, based on the reduction of proteinuria. Its long-term impact on slowing kidney function decline is still being […]
Komzifti Ziftomenib
Komzifti is an advanced anticancer therapy developed for the treatment of adults with relapsed or refractory Acute Myeloid Leukemia (AML) harboring a susceptible Nucleophosmin 1 (NPM1) mutation. It is specifically indicated for patients who have no satisfactory alternative treatment options, addressing a critical unmet medical need in high-risk AML management. Designed to target the molecular […]
Redemplo Plozasiran
Redemplo (plozasiran) is a targeted therapy approved for the treatment of familial chylomicronemia syndrome (FCS) in adults, in combination with a strict low-fat diet. FCS is a rare genetic lipid disorder in which the body cannot properly break down fats, leading to extremely high triglyceride levels and recurrent episodes of acute pancreatitis. Redemplo is designed […]
Hyrnuo Sevabertinib
Hyrnuo (sevabertinib) is an oral targeted therapy used to treat adults with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) that has HER2 (ERBB2) tyrosine kinase domain activating mutations. It is prescribed after patients have received at least one prior systemic therapy. Hyrnuo works by blocking HER2-driven tumor growth and is taken twice […]
Jascayd-Nerandomilast
Jascayd is an orally administered small-molecule therapy indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. It works by inhibiting multiple fibrotic and inflammatory signaling pathways involved in lung tissue scarring, thereby slowing disease progression and preserving pulmonary function. Through targeted modulation of fibroblast activity and reduction of extracellular matrix deposition, Jascayd helps […]
Lynkuet-Elinzanetant
Lynkuet is the first and only dual neurokinin 1 and 3 (NK1/NK3) receptor antagonist approved for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. By blocking NK1 and NK3 receptor signaling in the hypothalamic thermoregulatory center, Lynkuet helps reduce the frequency and severity of hot flashes, both during the day and at […]
Kygevvi-Doxecitine And Doxribtimine
Kygevvi is the first FDA-approved oral therapy for the treatment of Thymidine Kinase 2 Deficiency (TK2d) in adults and pediatric patients with symptom onset at 12 years of age or younger. TK2d is a rare, genetic mitochondrial disorder that leads to progressive muscle weakness and respiratory complications. Kygevvi works by replenishing deoxynucleoside levels to help […]
